Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies

Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identified, and does biomarker testing have a role? Where do the HER2-, HER3-, and TROP2-targeting therapies fit within the current treatment arsenal for advanced/metastatic NSCLC, and what is the best way to integrate them into practice? These and other questions are addressed by top experts in this PeerView MasterClass and Practicum. Faculty navigate through the evidence base, provide practical guidance regarding the clinical role and integration of novel ADCs, and discuss illustrative cases to help you better understand how to translate the science to practice and improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Review current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.